8 stars: A look back at ASCO spotlights the top cancer drugs to watch, and 1 to forget
I’ve been making the trek to ASCO for some years now, and I don’t recall any other week that rivals what I’ve just seen. There wasn’t just important data to report on, there was a lot of it.
CAR-T, with all of its splendid initial promise in liquid tumors, is reaching the first major commercial finish line, with Novartis’ $NVS CTL019 out in front of Kite’s $KITE KTE-C19 by a nose. Novartis waited to capture the industry’s attention at another conference mid-week with head-to-head data, but you better believe it figured prominently on my ASCO interview schedule.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.